Eli Lilly Submits New Data on Covid-19 Treatment Drug
October 28 2020 - 6:13PM
Dow Jones News
By Adriano Marchese
Eli Lilly & Co. said Wednesday that it has submitted new
data in its request for an emergency authorization from the Food
and Drug Administration for its drug bamlanivimab to treat mild
cases of Covid-19.
The Indianapolis-based company said that it has included in the
submission data published by the New England Journal of Medicine
from a Phase 2 study on the drug.
"The publication of these data in a peer-reviewed journal adds
to the growing body of evidence for the potential utility for
neutralizing antibodies as therapeutics for people recently
diagnosed with mild to moderate COVID-19, particularly high-risk
patients," said Ajay Nirula, vice president of immunology and
co-first author of the study.
The Phase 2 study was designed to assess the efficacy and safety
of bamlanivimab alone for the treatment of symptomatic Covid-19 in
the outpatient setting, the company said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 28, 2020 17:58 ET (21:58 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024